Related Quotes
IDB.TO
IDBE 8.42
5.3492 +0.16
+0.0992
delayed 20 mins - disclaimer
Quote Data provided by Reuters
Tuesday May 7, 12:13 pm Eastern Time
Press Release
SOURCE: ID Biomedical Corporation
ID Biomedical Corporation - Clinical Trial results of StreptAvax(TM) to be presented at international vaccine conference
TRADING SYMBOLS - NASDAQ - "IDBE", TSE - "IDB"
VANCOUVER, May 7 /CNW/ - ID Biomedical announced today that Dr. Shelly McNeil of Dalhousie University in Halifax will present Phase I Clinical Trial results for StreptAvax(TM) at the Fifth Annual Conference on Vaccine Research. Dr. McNeil's presentation will describe the first study in humans of StreptAvax(TM), ID Biomedical's multivalent recombinant vaccine developed to prevent group A streptococcus infections. The full presentation will be available on the company's website, www.idbiomedical.com on Friday May 10, 2002.
The National Foundation for Infectious Diseases (NFID), a sponsor of the conference, issued a press release today highlighting the clinical trial results of StreptAvax. The StreptAvax presentation was chosen by NFID because it "represents cutting edge development in the field, and holds great promise for improving public health in the US and abroad." The purpose of this press release was to call attention to two selected presentations from the conference, which will disclose particularly important scientific information and findings. See press release - WORLD'S VACCINE EXPERTS MEETING IN BALTIMORE TO REPORT NEW PROGRESS IN VACCINE DEVELOPMENT in our press release section on our website.
"The presentation of the results of the human testing of StreptAvax is historic," said Dr. Anthony F. Holler, ID Biomedical's Chief Executive Officer. "The data supports StreptAvax to be safe and broadly immunogenic in the human volunteers tested. This clinical trail is the first human study that suggests the development of a safe and effective group A strep vaccine is possible. I would like to thank all the organizations involved in achieving this challenging and important milestone including: our internal development team, Clinical Trial Research Center of Dalhousie University, the University of Tennessee, the National Institutes of Allergy and Infectious Diseases and regulatory authorities in Canada and the United States. On behalf of ID Biomedical and our collaborators I would also like to thank the NFID for recognizing the importance of our development efforts."
The Fifth Annual Conference on Vaccine Research is a non-commercial scientific forum that brings together specialists from diverse disciplines, such as microbiology, immunology, epidemiology and public health. The Conference is jointly sponsored by eight prestigious groups: the National Foundation for Infectious Diseases, the Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases, the International Society for Vaccines, the United States Department of Agriculture, the Center for Biologics Evaluation and Research of the Food and Drug Administration, the Albert B. Sabin Institute of Georgetown University, the Center for Vaccine Development at the University of Maryland, and the World Health Organization.
About ID Biomedical
ID Biomedical is a North American based biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology. ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology.
ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company's lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a number of vaccines in preclinical development.
ID Biomedical is licensing Cycling Probe Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further product and technology development. Several companies have obtained rights to ID Biomedical's patent portfolio.
The foregoing information contains so-called forward-looking statements.
These include statements about ID Biomedical's expectations, beliefs,
intentions or strategies for the future, which it indicates by words or
phrases such as "anticipate", "expect", "intend", "plan", "will", "we
believe", "ID Biomedical believes", "management believes" and similar
language. All forward-looking statements are based on ID Biomedical's current
expectations and are subject to risks uncertainties and to assumptions made.
Important factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include: (i) the
ability to successfully complete preclinical and clinical development of its
products; ii) the ability to obtain and enforce timely patent and intellectual
property protection for its technology and products; iii) the ability to
avoid, either by product design, licensing arrangement or otherwise,
infringement of third parties' intellectual property; iv) decisions, and the
timing of decisions, made by the health regulatory agencies regarding approval
of its products for human testing; v) the ability to complete and maintain
corporate alliances relating to the development and commercialization of its
technology and products; vi) market acceptance of its technology and product;
and (vii) the competitive environment and impact of technological change. ID
Biomedical bases its forward-looking statements on information currently
available to it, and assumes no obligation to update them.
For further information
ID Biomedical Corporation, Dean Linden, Manager, Corporate Communications, (604) 431-9314, www.idbiomedical.com
To request a free copy of this organization's annual report, please go to newswire.ca and click on reports@cnw. |
